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Results: Out of 1689 enrolled pts, 659 pts (39.02%) received Triple and 1030 pts (60.98%) Dual therapy. Pts with Cilostazol group had more male (69.8% vs. 64.1%, P=0.015), worse baseline angiographic characteristics including more bifurcation (34.6% vs. 28.9 %, P=0.001), left main (7.9% vs. 2.3%, P<0.001), diffuse long (34.1% vs. 26.8%, P=0.001) and Ostial Lesions (19.9% vs. 13.9%, P=0.001). Despite the higher risk subset of pts in Cilostazol group, major clinical hard endpoints, incidence of stent thrombosis and angiographic outcomes were similar between the two groups (Table) .
Conclusion:
Triple antiplatelet therapy including adjunctive Cilostazol in high risk pts undergoing PCI with DES in real world clinical practice showed similar midterm clinical and angiographic outcomes compared with those of usual pts with dual antiplatelet therapy. 
